The New York-based company said preparations are underway to initiate a Phase 1 study in the third quarter of intranasal racemic ketamine (SLS-002) to further evaluate the pharmacokinetics, pharmacodynamics, and drug-to-drug interactions in patients with post-traumatic stress disorder who are at imminent risk of suicide.
Seelos also said the first patient with Sanfilippo Syndrome is expected to be dosed with Trehalose (SLS-005) in an FDA/EMA open-label Phase 2b/3 trial in the third quarter of 2019.
Sanfilippo Syndrome is a rare disease in which the body doesn’t have certain enzymes to break down long chains of sugar molecules and can be fatal in some cases. Children with the syndrome develop a developmental disability and seizures. Patients usually live into adolescence or early adulthood.
Lastly, the company said it has initiated in the current quarter a peptide-based approach targeting the NACore (nonamyloid component core) in Parkinson’s disease in a proof-of-concept, in-vivo delivery of SLS-007 in a transgenic mice model.
Seelos’ stock recently traded down 1.8% to $2.77 a share.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham